Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
Gilead Sciences, Inc. Appoints Dr. John J. Toole as Senior Vice President, Corporate Development
3/7/2008
-
POINT Biomedical Corporation Announces Gilead Sciences, Inc.'s Madeline Miller, D.V.M., Hired as VP, Clinical Operations
3/4/2008
-
Gilead Sciences, Inc. Announces $500 Million Accelerated Share Repurchase
3/3/2008
-
Gilead Sciences, Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5
1/31/2008
-
Gilead Sciences, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
1/24/2008
-
Mixed Earnings Forecast for Big Pharma
1/23/2008
-
Gilead Sciences, Inc. Announces Departure of Caroline Dorsa
1/21/2008
-
Gilead Sciences, Inc. to Release Fourth Quarter and Year End 2007 Financial Results on Wednesday, January 23, 2008
1/17/2008
-
Gilead Sciences, Inc. to Present at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7
1/4/2008
-
Gilead Sciences, Inc.: European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
12/17/2007
-
European Commission Approves ATRIPLA(R), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
12/17/2007
-
Gilead Sciences, Inc. to Present at the NASDAQ 20th Investor Program on Thursday, December 6
11/29/2007
-
PARI Pharma's eFlow Included in Gilead Sciences, Inc.'s NDA Submission for Aztreonam Lysine for Inhalation
11/26/2007
-
Gilead Sciences, Inc. to Present at the 19th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
11/20/2007
-
Gilead Sciences, Inc. Submits New Drug Application to U.S. FDA for Aztreonam Lysine for Inhalation for Cystic Fibrosis
11/16/2007
-
Gilead Sciences, Inc. to Present at the 2007 Credit Suisse Healthcare Conference on Wednesday, November 14
11/8/2007
-
Gilead Sciences, Inc. and LG Life Sciences, Ltd. Announce Global License Agreement to Advance Novel Drug Candidates for Treatment of Fibrotic Diseases
11/7/2007
-
Gilead Sciences, Inc. Hepatitis Drug May Have Heart Issue-Study
11/5/2007
-
Gilead Sciences, Inc. Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
11/2/2007
-
Gilead Sciences, Inc. Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
10/29/2007